April 2026 Research Update

This month added a clearer picture of how autoimmune hemolytic anemia (AIHA) is being treated in real-world settings and what is being tried when standard approaches do not work. Across studies, steroids remained the most common starting point, and adding rituximab (a B-cell targeting antibody) was linked with better response in two different patient groups. Several single-patient reports also described improvement after more specialized immune therapies, but these are early signals rather than proof of what works for most people. [1] [2] [3] [4] [5] [6]

In a 50-person prospective study, most patients improved with steroid treatment, and some needed additional medicines, while the direct antiglobulin test (DAT, a blood test that can support the diagnosis) often stayed positive even after laboratory values corrected at 9 months. This is a helpful reminder that some lab tests may lag behind symptoms and blood counts, at least in some patients. The same study also reported that transfusion support with best-match blood units was used for many patients. [1]

In a larger 125-person retrospective hospital study, first-line glucocorticoids (steroids) were the most common approach, but glucocorticoids plus rituximab had higher reported response and more sustained remission than steroids alone. The study also reported that infections and blood clots in veins occurred in this patient population, and that needing more lines of treatment was linked with more infections. It also described that some relapsed or refractory patients received exploratory newer targeted drugs, with some reaching remission or hemoglobin normalization after treatment. [2]

A separate transplant-focused study looked at AIHA that develops after allogeneic stem cell transplantation and found that corticosteroids plus rituximab was linked with improved treatment response without major safety concerns reported in that dataset. This study also reported relapse and mortality rates in this higher-risk setting, emphasizing that post-transplant AIHA can behave differently than AIHA outside of transplant. [3]

Several case reports described responses after treatments usually considered only when disease is difficult to control. Two different single-patient reports of CD19 CAR T-cell therapy (a cell-based immune therapy) described rapid improvements in hemoglobin and platelets in severe or refractory Evans syndrome/AIHA, with limited short-term toxicity reported in those individuals. Another case report described a rapid response to linperlisib (a PI3K inhibitor) in relapsed/refractory AIHA, but details beyond the rapid response were limited in the summary provided. [4] [5] [6]

For patients and caregivers, this month most strongly adds context about what treatment sequences often look like and why some people end up needing additional therapies. The best-supported new information here is observational: in routine care, adding rituximab to steroids was linked with better reported outcomes than steroids alone in two cohorts, including a post-transplant setting. The newer therapies (like CAR T cells or linperlisib) are still mainly early research signals because they were reported in single patients, so it is not yet clear who benefits most, how durable responses are across larger groups, or what risks look like in broader use. [2] [3] [4] [5] [6]

These studies also help clarify that lab tests do not always track perfectly with recovery. In one prospective cohort, the DAT often remained positive months after other lab values corrected, which can be confusing if you expect every test to normalize at the same time. This does not prove what should be monitored or how often, but it does explain why some results may not immediately match how someone is doing clinically. [1]

Studies focused on cold-type autoimmune hemolytic anemia this month made one point clearer: many people labeled as cold agglutinin disease (CAD) have evidence of an underlying B-cell clone (an abnormal group of immune cells), even when the bone marrow does not look strongly abnormal under the microscope. This matters because it supports the idea that cold-type disease is often connected to a subtle immune cell disorder, and classification can require more sensitive testing than a standard pathology look alone. [7] [8]

In a 56-person pathology cohort, 18% had an overt B-cell cancer explaining their cold agglutinin syndrome, while almost all of the remaining patients still showed some evidence of clonality by blood proteins or bone marrow testing. Only a small fraction met strict newer morphological criteria for a specific CAD-related bone marrow pattern, even when clonality was present. Put simply, these patients often had measurable signs of a B-cell clone, but the bone marrow appearance alone did not consistently fit a narrow definition. [7]

A separate Japanese cohort study also highlighted that CAD is not one single uniform condition. Among patients who received detailed review, some matched primary CAD, some overlapped with indolent B-cell lymphoma patterns, and some had very few detectable tumor cells, yet many were still ultimately classified as primary CAD. This helps explain why two people with a similar label may have different underlying biology. [8]

Treatment-focused case reports in cold agglutinin conditions described improvement when therapy targeted the underlying driver. One patient with marginal zone lymphoma and cold agglutinin syndrome improved after switching from rituximab alone to rituximab plus lenalidomide, with cold agglutinin tests becoming negative and remission reported for 24 months. Another case described refractory CAD with hypersplenism where splenectomy followed by restarting sutimlimab (a complement pathway drug) was followed by marked and sustained blood count improvement. [9] [10]

For patients, this set of studies mainly adds understanding of why cold-type AIHA workups can feel more complex than expected. Multiple groups reported that evidence of an underlying B-cell clone is very common in CAD, even when the bone marrow does not meet strict visual criteria, which may explain why different tests are sometimes needed to fully characterize the condition. These studies do not say what any one person should do, but they make it clearer that the label "CAD" can include different underlying situations, including cases linked to an identifiable lymphoma. [7] [8]

The treatment case reports may matter later if confirmed in larger groups, especially for people with difficult-to-control cold agglutinin disease or cold agglutinin syndrome linked to lymphoma. Because they describe single individuals, they cannot predict what will happen for most patients, but they do show the kinds of strategies being tried when standard options have not worked. [9] [10]

This month’s case reports showed that AIHA can appear in many different medical situations, including infections, autoimmune conditions, pregnancy, and after certain drugs. The shared message is not that these situations always cause AIHA, but that clinicians sometimes had to look beyond the most obvious explanation (like transfusion reaction or infection alone) to recognize immune-driven red blood cell destruction. Several cases also illustrated that the direct antiglobulin test (DAT) can be positive, negative, or change over time, depending on the situation. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21]

Infections were reported as settings where AIHA or related syndromes showed up, but the timing differed across cases. One hospitalized patient with advanced HIV and cerebral toxoplasmosis developed warm AIHA more than 2 months into admission and improved with corticosteroids, with no relapse reported. Another case described cold agglutinin syndrome after Mycoplasma pneumoniae, with severe hemolysis and a DAT consistent with complement involvement. [14] [21]

Several cases highlighted special diagnostic challenges, including situations where common tests could be misleading. One pregnancy case described extremely low HbA1c that masked gestational diabetes, with AIHA thought to shorten red blood cell lifespan and lower HbA1c readings. Another report described DAT-negative hemolysis with severe thrombocytopenia during acute pancreatitis, where the diagnosis remained a clinical working diagnosis after other causes were excluded, and counts improved after IVIG and steroids. [16] [13]

Pregnancy and autoimmune overlap conditions were also represented. A pregnant woman with ulcerative colitis flare and steroid-refractory warm AIHA improved after escalation that included rituximab, with hemolysis resolving and transfusion dependence ending; the newborn had respiratory distress but no hemolysis was reported. Another case described warm-type AIHA occurring alongside autoimmune polyendocrine syndrome type 3C and primary hyperparathyroidism, with anemia improving on prednisolone and calcium-related labs normalizing after parathyroid surgery. [19] [11]

Drug- and treatment-associated immune hemolysis was reported in a few different forms. Two cancer patients developed AIHA after PD-1 immune checkpoint inhibitor therapy, described as a rare immune-related side effect. Another case described abrupt warm AIHA soon after starting venetoclax with azacitidine for acute myeloid leukemia, improving after stopping venetoclax and starting corticosteroids, with compensated hemolysis on rechallenge. [17] [20]

One report underscored that drug-induced immune hemolysis can be severe and may be confused with transfusion reactions at first. In that case, ceftriaxone-induced immune hemolytic anemia was confirmed by specialized testing after an initial concern for a delayed hemolytic transfusion reaction, and the clinical course progressed to multi-organ failure and death. This case mainly adds awareness that confirmatory immunohematology testing exists when the trigger is uncertain. [15]

Finally, one pediatric case described severe anemia in a 16-month-old with sepsis-associated AIHA, managed with intensive resuscitation including large-volume transfusion through intraosseous access and antibiotics, with recovery of hemoglobin and later negative Coombs tests at 5 months without immunotherapy. Another case of newly diagnosed systemic lupus erythematosus and antiphospholipid syndrome described complex multi-organ illness with improvement after intensive immune treatment, illustrating how AIHA can occur in broader autoimmune disease contexts, although the report focused on the overall lupus presentation. [12] [18]

For patients and caregivers, these case reports mainly help explain the range of real-life situations where AIHA can emerge, and why doctors sometimes need to revisit the cause of anemia during an illness or after starting a new medicine. Because each report describes 1 person (or 2 people), the findings cannot be used to estimate how often these events happen, but they can clarify what kinds of triggers have been observed and how varied the workup can be. This information is most useful for understanding the condition rather than changing anything immediately. [12] [13] [14] [21] [17] [20]

A practical takeaway from these reports is that AIHA can complicate other health issues and can also affect interpretation of other lab tests. The pregnancy report on falsely low HbA1c is an example of how red blood cell breakdown can distort a common diabetes marker, and the drug-induced hemolysis reports show that pinpointing a trigger can require specialized testing. What remains uncertain is how widely these specific scenarios apply, since case reports cannot show typical outcomes across larger groups. [16] [15]

Two dog studies explored risk signals and organ involvement in immune-mediated hemolytic anemia (IMHA), which is related to AIHA but occurs in animals. One study suggested that certain urine markers may reflect kidney involvement and may relate to prognosis in dogs with suspected IMHA. Another study found a higher proportion of recent vaccination in dogs with IMHA than in control dogs, but emphasized that this timing signal does not prove vaccines caused IMHA. [22] [23]

In a 21-dog prospective veterinary study, the urine protein-to-creatinine ratio was higher than in controls and tracked with how severe the anemia and inflammation were, and urinary bilirubin was also elevated and reported as a prognostic indicator. In plain language, this suggests that kidney stress and breakdown products from hemolysis may show up in urine and may help reflect how sick an animal is. This is animal research and does not directly tell us what will happen in people with AIHA. [22]

In a multicenter retrospective case-control study in dogs, IMHA cases were more likely than controls to have had a vaccine in the prior 30 days, and a meta-analysis across studies suggested the odds were more than twice as high, with results varying across studies. The same analysis did not find a clear timing relationship for immune-mediated thrombocytopenia (ITP). The authors noted important limitations, including that observational timing data cannot prove cause and effect. [23]

For patients and caregivers, these studies are mainly background science rather than directly applicable evidence, because they were done in dogs with IMHA. They can still be helpful for understanding what researchers are watching for, such as signs of kidney involvement during immune hemolysis and how timing studies are used to explore possible triggers. What remains uncertain is how closely these patterns match human AIHA, since animal disease and veterinary care do not fully mirror human illness. [22] [23]